Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of NRP104 administered
as a daily morning dose (30, 50, and 70mg/day) compared to placebo in adults (18-55 years of
age inclusive) diagnosed with moderate to severe Attention Deficit Hyperactivity Disorder
(ADHD).